BriaCell Therapeutics (TSE:BCT) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BriaCell Therapeutics is set to present updated survival data and key findings from its Phase 2 trial of Bria-IMT™ at the upcoming San Antonio Breast Cancer Symposium. These presentations will highlight the potential expansion of their cancer immunotherapy to patients with central nervous system metastases. The company’s developments showcase a commitment to advancing cancer treatment through innovative research.
For further insights into TSE:BCT stock, check out TipRanks’ Stock Analysis page.